Cadence Neuroscience
Cadence Neuroscience is a clinical-stage medical device company developing an implantable biomarker-targeted neuromodulation system for adults and children with drug-resistant focal epilepsy, based on technology exclusively licensed from Mayo Clinic.
- Company typePrivate
- Founded2017
- HeadquartersRedmond, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cadence Neuroscience does
Cadence Neuroscience, Inc. is a privately held, clinical-stage medical device company founded in 2017 and headquartered in Redmond, Washington (incubated at Mayo Clinic in Rochester, Minnesota). The company is developing an implantable neuromodulation system called the Cadence Neuromodulation System, also referred to as Biomarker Targeted Stimulation (BTS), for the treatment of drug-resistant focal epilepsy in adults and children. The system combines established neuromodulation hardware with proprietary software that monitors real-time EEG biomarkers and adaptively adjusts stimulation parameters for each patient, distinguishing it from fixed or reactive stimulation approaches such as VNS, RNS, and DBS.
The technology was developed at Mayo Clinic over more than 10 years of clinical use and is exclusively licensed to Cadence. Early clinical data indicates that approximately 50% of patients treated with the therapy achieved seizure freedom, materially exceeding reported outcomes for existing neuromodulation alternatives (VNS ~6%, RNS ~8%, DBS ~12%). Cadence is pursuing regulatory clearance via the FDA Humanitarian Device Exemption pathway and received approval of its Investigational Device Exemption in mid-2026, with a pivotal clinical study planned later that year. The company is supported by strategic and financial partners including Mayo Clinic, Angelini Ventures, F-Prime, JAZZ Venture Partners, Lumira Ventures, Mayo Foundation, and LivaNova, with cumulative funding of approximately $41 million across a $15 million Series A (2019) and a $26 million Series B (2023).
The business model centers on hardware sales of the implantable neuromodulation device to hospitals and specialized epilepsy treatment centers following regulatory approval. Until then, the device is available only through clinical trial participation. Go-to-market activities are primarily clinical and regulatory, supported by direct engagement with epilepsy centers (Mayo Clinic, Cook Children's Hospital), participation in the American Epilepsy Society Annual Meeting, and content/community programs including the Seizure Diaries podcast. The company has grown to more than 30 employees and contractors as of 2025.
Cadence Neuroscience firmographics
Firmographics- Name
- Cadence Neuroscience
- Legal name
- Cadence Neuroscience, Inc.
- Website
- https://cadenceneuro.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cadence Neuroscience is a clinical-stage medical device company developing an implantable biomarker-targeted neuromodulation system for adults and children with drug-resistant focal epilepsy, based on technology exclusively licensed from Mayo Clinic.
- Ownership category
- akta.pro rank
Cadence Neuroscience industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote DiagnosticsNeurology RPM (epilepsy, Parkinson’s, MS monitoring)Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
Keywords
Where Cadence Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Redmond
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cadence Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Neuromodulation medical device sales: Cadence Neuroscience is developing an implantable neuromodulation device for drug-resistant epilepsy. Upon regulatory approval, the company is expected to commercialize the device through direct sales to hospitals and epilepsy treatment centers, generating revenue from device sales and potentially associated services.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Cadence Neuroscience product offering
Product offeringCore offering
Cadence Neuroscience is developing the Cadence Neuromodulation System, an investigational implantable medical device that delivers personalized, biomarker-targeted brain stimulation for adults and children with drug-resistant focal epilepsy. The system combines proven neuromodulation hardware with proprietary software that monitors EEG biomarkers in real time and continuously adjusts stimulation parameters for each patient. The therapy is exclusively licensed from Mayo Clinic, where it has been studied in patients for over a decade.
Product overview
Cadence Neuroscience offers a single unified product—the Cadence Neuromodulation System (also referred to as BTS or Biomarker Targeted Stimulation). This is an investigational medical device for treating drug-resistant focal epilepsy, developed in collaboration with Mayo Clinic. The system combines proven neuromodulation hardware technology with proprietary personalized software algorithms. The therapy monitors each patient's brain activity in real-time and adjusts stimulation parameters based on observed brain responses, making it a personalized treatment approach rather than a one-size-fits-all solution.
Differentiator
Problem solved
Functional benefit
Products and services
- Cadence Neuromodulation System (Biomarker Targeted Stimulation) Investigational implantable neuromodulation device that delivers small, precise electrical pulses guided by real-time EEG biomarkers to prevent seizures in patients with drug-resistant focal epilepsy. Combines time-tested hardware materials with proprietary biomarker-targeted stimulation software licensed from Mayo Clinic. Currently accessible only through participation in a clinical trial.
Quantifiable outcome
- Approximately 50% of patients treated with Cadence's biomarker targeted stimulation therapy became seizure-free, compared to approximately 6% for VNS, 8% for RNS, and 12% for DBS.
- +1 more outcomes
Companies that use Cadence Neuroscience
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Cadence Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cadence Neuroscience partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Cook Children's Hospital (Jane and John Justin Institute for Mind Health)coreCook Children's Hospital is a key clinical collaborator for Cadence Neuroscience. The hospital, one of the busiest level 4 pediatric epilepsy centers in the nation, is engaged with Cadence for clinical studies involving pediatric epilepsy patients. Dr. Scott Perry serves as a key clinical collaborator and podcast guest, discussing neuromodulation approaches and patient care.
- Mayo CliniccoreCadence Neuroscience was incubated at Mayo Clinic and holds an exclusive license to Mayo Clinic's biomarker targeted stimulation (BTS) technology for epilepsy. Mayo Clinic researchers (including Dr. Greg Worrell and Dr. Matt Stead) developed the therapy which has been used with success in clinical trials for over 10 years. Cadence continues to collaborate closely with Mayo Clinic on ongoing clinical studies and technology development.
- MCRA (IQVIA business)majorMCRA is Cadence's regulatory consulting partner, providing strategic guidance on FDA regulatory pathways (including the Humanitarian Device Exemption). MCRA's team includes former FDA staff with deep expertise in neurological devices, helping Cadence navigate the complex FDA submission and review process.
- Mayo Clinic (continued)coreMayo Clinic serves as Cadence's primary research and clinical development partner. Cadence's therapy is based on Mayo Clinic research and is being advanced through Mayo Clinic's ongoing clinical study, where patients undergo invasive monitoring and biomarker targeted stimulation testing. Dr. Greg Worrell (Mayo Clinic) is a key collaborator featured on Cadence's Seizure Diaries podcast.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Cadence Neuroscience competitors and assessment
Company assessmentEmerging players
- Saluda Medical: Saluda Medical is developing closed-loop spinal cord stimulation systems with Evoked Compound Action Potential (ECAP) feedback, making it a relevant comparable for biomarker- or physiology-driven adaptive neurostim technology analogous to Cadence's BTS approach.
- Nalu Medical: Nalu Medical offers a miniaturized, externally-powered implantable neurostim system for chronic pain, providing a comparable for an emerging implantable neurostim company focused on device miniaturization and novel form factors in a specialty indication.
- Mainstay Medical: Mainstay Medical markets an implantable restorative neurostimulation system for chronic mechanical low back pain. It is a relevant emerging-stage comparable for a clinical-to-commercial neuromodulation company navigating payer and adoption challenges in a defined specialty population.
- Axonics: Axonics develops implantable sacral neuromodulation systems for incontinence and offers a successful playbook for scaling a smaller neuromodulation device company from clinical-stage to commercial-stage against large incumbents. Technology and business model overlap in the implantable stim category.
Broad incumbents
- Medtronic: Medtronic sells Deep Brain Stimulation (DBS) systems with FDA-approved epilepsy indications, alongside a broad neuromodulation portfolio spanning Parkinson's, chronic pain, and other conditions. It represents the broadest commercial-scale neuromodulation incumbent Cadence would compete against for epilepsy share of mind.
- Abbott: Abbott's neuromodulation business (formerly St. Jude Medical) markets DBS and spinal cord stimulation systems, with active research into closed-loop and adaptive stimulation architectures. It is a broad incumbent in the same technology category Cadence operates in.
- Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostimulation device for obstructive sleep apnea, providing a relevant comparable for the regulatory, clinical-trial, and commercial path of an implantable neurostim company in a focused specialty indication.
- Boston Scientific: Boston Scientific's Neuromodulation division offers Vercise DBS systems and is investing in next-generation directional and sensing-enabled stimulation. As a large commercial incumbent in implantable neurostim, it is a relevant comparable for Cadence's go-to-market and pipeline trajectory.
Direct peers
- NeuroPace: NeuroPace developed the RNS System, a direct closed-loop neurostimulation device for drug-resistant focal epilepsy. It is the most direct commercial-stage competitor to Cadence's BTS neuromodulation system, targeting the same patient population with an EEG-responsive stimulation paradigm.
- LivaNova: LivaNova markets the Vagus Nerve Stimulation (VNS) Therapy system, the most established neuromodulation treatment for drug-resistant epilepsy. LivaNova is also a current Cadence investor, making it both a competitor and a strategic capital partner with deep overlap in the same patient population.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Cadence Neuroscience social profiles
Digital presenceCadence Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cadence Neuroscience leadership team
Management profileNumber of profiles
Profiles8 records
Cadence Neuroscience funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cadence Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cadence Neuroscience
What does Cadence Neuroscience do?
Cadence Neuroscience is developing the Cadence Neuromodulation System, an investigational implantable medical device that delivers personalized, biomarker-targeted brain stimulation for adults and children with drug-resistant focal epilepsy. The system combines proven neuromodulation hardware with proprietary software that monitors EEG biomarkers in real time and continuously adjusts stimulation parameters for each patient. The therapy is exclusively licensed from Mayo Clinic, where it has been studied in patients for over a decade.
Is Cadence Neuroscience a public or private company?
Cadence Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cadence Neuroscience founded?
Cadence Neuroscience was founded in 2017. It employs 11 to 50 people.
Where is Cadence Neuroscience based?
Cadence Neuroscience is headquartered in Redmond, United States, in the North America region.
How does Cadence Neuroscience make money?
One revenue line is on record: neuromodulation medical device sales.
Who are Cadence Neuroscience's main competitors?
Emerging players on record are Saluda Medical, Nalu Medical, Mainstay Medical and Axonics. Broad incumbents are Medtronic, Abbott, Inspire Medical Systems and Boston Scientific. Direct peers are NeuroPace and LivaNova.
Does Cadence Neuroscience have an API?
No public API is recorded for Cadence Neuroscience.
What industry is Cadence Neuroscience in?
Cadence Neuroscience's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.